Clinical Trial Update: SU5416 in Treating Children With Recurrent or Progressive Brain Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating SU5416 (semaxanib) in children with recurrent or progressive brain tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumors
• Central Nervous System Tumors

Drugs mentioned

• SU5416 (semaxanib)

Snippet

Sponsor: Pediatric Brain Tumor Consortium | Conditions: Brain and Central Nervous System Tumors | Phase 1 | Status: TERMINATED